CDK4/6 inhibitor
Ribociclib (Specialist drug)
Brand names: Kisqali
Adult dose
Dose: Specialist initiation only — refer to BNF/SmPC
Route: PO
Frequency: OD x 21 days q28
Clinical pearls
- HR+ HER2- advanced/metastatic breast cancer with endocrine therapy
- ECG and electrolytes pre-treatment + during
Contraindications
- QT prolongation
- Concurrent strong CYP3A4 inhibitors
- Severe hepatic impairment
Side effects
- Severe neutropenia
- QT prolongation
- Hepatotoxicity
- ILD/pneumonitis
- Severe skin reactions (SJS/TEN)
Interactions
- Strong CYP3A4 modulators
- QT-prolonging drugs
- Tamoxifen (avoid concomitant)
Monitoring
- FBC
- LFTs
- ECG
- Electrolytes
Reference: BNF; NICE TA496/TA593; SmPC; https://bnf.nice.org.uk/drugs/ribociclib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
Drugs